Testing a New Treatment for Multifocal Motor Neuropathy
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests a new medicine called empasiprubart in adults with multifocal motor neuropathy (MMN), a rare condition affecting nerve function. The trial uses ultrasound to see if the medicine can help reduce nerve thickening and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older
- You have been diagnosed with multifocal motor neuropathy (MMN)
- Your MMN symptoms are at a moderate level (not in the top 10% of severity)
- Ultrasound imaging has shown thickening in at least one of your nerves
- You do not have other active autoimmune diseases that could interfere with the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
This trial tests a new medicine called empasiprubart in teenagers ages 12–17 with CIDP, a rare nerve disease that causes weakness and numbness. Researchers want to find the right dose and see if it safely reduces symptoms.
This trial tests a new drug called empasiprubart for people with generalized myasthenia gravis (gMG) who have a certain antibody (AChR-Ab). It is given as a monthly IV infusion (into a vein) and aims to improve muscle weakness and daily functioning.
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
This study tests whether a new experimental medicine called CC-97540 is safe and well-tolerated in patients with a rare neurological disease called neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody marker (anti-AQP4). The trial involves a procedure that removes and reprocesses some of your immune cells.
Hear when a new Multifocal Motor Neuropathy (MMN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.